|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC):a multicentre,open-label,randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
| 2 | Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: An intergroup study FNCLCC cleo0d-IFCT 00-01 显示文摘 | Pujol JL Breton JL Gervais R | 2007 | J Clin Oncol2007，25，25： | 1 |
| 3 | Phase Ⅱ randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)显示文摘 | Gervais R Ducolone A Breton J L | 2005 | Ann Oncol2005，16，1： | 1 |
| 4 | Effect of grain and forage fractions of corn silage on milk production and composition in dairy cows 显示文摘 | Boivin M Gervais R Chouinard PY | 2013 | Animal2013，7，2： | 1 |
| 5 | Constrained multivariable control of a distillation column using a simplified model predictive control algorithm显示文摘 | Abou-Jeyab R A Gupta Y P Gervais J R | | 0，，05： | 1 |
| 6 | Erlotinib versuschemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemo-therapy (EURTAC) phase III randomized trial 显示文摘 | Rosell R Gervais R Vergnenegre A | 2011 | J Clin Oncol2011，29，15： | 1 |
| 7 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advaneed EGFR mutation-positive non-small-cell lung cancer (EURTAC) : a multicentre, open-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncnl2012，13，3： | 1 |
| 8 | Surface electrocardio- gram to predict outcome in candidates for cardiac resynchroniza- tion therapy: a sub-analysis of the CARE-HF trial显示文摘 | Gervais R Leclercq C Shankar A | 2009 | Eur J Heart Fail2009，11，： | 1 |
| 9 | Children's persistent lying,gender differences,and disruptive behaviours:A longitudinal perspective显示文摘 | Tremblay R E Gervai L D | 2000 | International Journal of Behavioral Development2000，，2： | 1 |
| 10 | Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cance 显示文摘 | Gervais R Hainsworth J D Blais N | 2011 | Lung Cancer2011，74，3： | 1 |
| 11 | Phase Ⅱ randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced nonsman-cell lung cancer (NSCLC)显示文摘 | Gervais R Ducolone A Breton JL | 2005 | Ann Oncol2005，16，1： | 1 |
| 12 | Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations:interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial显示文摘 | Rosell R Gervais R Vergnenegre A | | 0，，： | 1 |
| 13 | Impact of Probiotics on Risk Factors for Cardiovascular Diseases. A Review显示文摘 | Bruno Ebel Guillaume Lemetais Laurent Beney Rémy Cachon Harry Sokol Philippe Langella Patrick Gervais | 2014 | Critical Reviews in Food Science and Nutrition2014，，2： | 1 |
| 14 | Phase Ⅲ study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer 显示文摘 | Ramlau R Gervais R Krzakowski M | 2006 | J Clin Oncol2006，24，18： | 1 |
| 15 | Erlotinib versus stan- dard chemotherapy as first-line treatment for European pa- tients with advanced EGFR mutation-positive non-small cell lung caucer(EURTAC) :a muhicentre,open-label,randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R et a| | 2012 | Lancet Oncol2012，13，3： | 1 |
| 16 | A rationale for retrievability of fixed, implant-supported prostheses: a complication-based analysis显示文摘 | Gervais M J Wilson P R | 2007 | International Journal of Prosthodontics2007，20，1： | 1 |
| 17 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer ( EURTAC ) : a multicentre, open-label, randomised phase 3 trial 显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，23： | 1 |
| 18 | Phase III double-blind,placebo-controlled study of thalidomide in extensive disease small cell lung cancer after response to chemotherapy显示文摘 | Pujol JL Breton JL Gervais R | 2007 | Clin Oncol2007，25，25： | 1 |
| 19 | Implementation of functional autonomy measurement system: barriers and facilitators in PISE-Dordogne project显示文摘 | Gervais P Hebert R Lamontagne J | 2011 | Geriatric et psychol- ogic neuropsychiatrie du vieillissement2011，9，： | 1 |
| 20 | Erlotinib versus stand- ard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial显示文摘 | Rosell R Carcereny E Gervais R | 2012 | Lancet Oncol2012，13，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员